Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia
Eur J Haematol 2003: 70: 373–378. © Blackwell Munksgaard 2003. Abstract: Background and Methods:
Serum levels of matrix metalloproteinase-9 (MMP-9) which agree with progression in solid and haematological tumours were correlated to the risk of disease progression in 62 patients with early (Binet stage A) B-cell chronic lymphocytic leukaemia (CLL). Sera were taken at diagnosis and tested by an enzyme-linked immunosorbent assay. Results:
MMP-9 levels positively correlated with haemoglobin levels (P = 0.03) and platelet count (P = 0.03). No association was found with main clinico-haematological features representative of tumour mass, such as peripheral blood lymphocytosis, bone marrow histology, Rai substages and -2 microglobulin (-2m). A cut-off of MMP-9 levels corresponding to 33rd percentile (203 ng/mL) or higher identified earlier upstaging and shorter progression-free survival. MMP-9 was a significant prognostic marker in multivariate analysis and partially independent of Rai substages, which suggests its inclusion into such a staging system to better stratify prognostically Rai stages I and II patients. Conclusions:
MMP-9 serum levels predict disease behaviour and help to refine the prognosis of stage A CLL patients.
Document Type: Research Article
Affiliations: 1: Medical Oncology Unit, Azienda Ospedaliera ‘Pugliese-Ciaccio’, Catanzaro; 2: Clinical Pathology Service, Istituto ‘Regina Elena’ IRCCS, Rome; 3: Department of Biomedical Sciences and Human Oncology, Bari and 4: Institute of Hematology, University of Ferrara, Ferrara, Italy
Publication date: June 1, 2003